The Safety and Efficacy of MULTIHANCE at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients Who Are Less Than 2 Years of Age

Trial Profile

The Safety and Efficacy of MULTIHANCE at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients Who Are Less Than 2 Years of Age

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2016

At a glance

  • Drugs Gadobenic acid (Primary)
  • Indications CNS disorders
  • Focus Diagnostic use
  • Sponsors Bracco Diagnostics
  • Most Recent Events

    • 18 Jul 2016 Status changed from recruiting to completed.
    • 19 May 2015 Status changed from not yet recruiting to recruiting, according to to ClinicalTrials.gov record.
    • 19 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top